Substance Use Disorder Policies

Date of last comprehensive review: 4/13/2020

Download CSV

State Use of telemedicine/telephone evaluations to initiate buprenorphine prescribing Patients can receive 14-28 take-home doses of opioid medication Home delivery of take-home medication by opioid treatment programs Use of telemedicine for schedule II-V prescriptions Exceptions to emergency oral prescriptions Waive requirement to obtain separate DEA registration to dispense outside home state Notes
Alabama------Mar 20, 2020----
Alaska------------
Arizona--------Mar 11, 2020--
Arkansas------------
California------------
Colorado------------
Connecticut------------
Delaware------------
District of Columbia------------
Florida------------
Georgia--------Apr 1, 2020--
Hawaii------------
Idaho------------
Illinois------------
Indiana------Mar 28, 2020----
Iowa------------
Kansas------------
Kentucky------------
Louisiana------------
Maine--Mar 24, 2020--------
Maryland------------
Massachusetts--------Apr 6, 2020--
Michigan------------
Minnesota------------
Mississippi--------Mar 30, 2020--
Missouri------------
Montana------------
Nebraska------------
Nevada----------Apr 8, 2020
New Hampshire--------Apr 6, 2020--
New Jersey------------
New Mexico------------
New York------Mar 27, 2020----
North Carolina------------
North Dakota------------
Ohio------------
Oklahoma------------
Oregon------------
PennsylvaniaMar 25, 2020Mar 18, 2020--Oct 24, 2019----
Notes
PA - State already allowed use of telemedicine to schedule II-V prescriptions as of 10/24/19
Rhode IslandApr 13, 2020--Apr 13, 2020------
South Carolina------------
South Dakota------------
Tennessee------------
Texas------------
Utah------------
Vermont------------
Virginia------------
Washington------------
West Virginia------Mar 31, 2020Mar 31, 2020--
Wisconsin------------
Wyoming------------
Total 2 2 1 5 6 1